Guggenheim Capital LLC Has $1.16 Million Holdings in Masimo Co. (NASDAQ:MASI)

Guggenheim Capital LLC increased its stake in shares of Masimo Co. (NASDAQ:MASI) by 61.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 7,021 shares of the medical equipment provider’s stock after purchasing an additional 2,674 shares during the period. Guggenheim Capital LLC’s holdings in Masimo were worth $1,161,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. FMR LLC lifted its stake in shares of Masimo by 19.8% in the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock worth $1,338,509,000 after buying an additional 1,340,836 shares during the last quarter. Vanguard Group Inc. lifted its position in Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock worth $758,182,000 after acquiring an additional 66,215 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock valued at $286,823,000 after acquiring an additional 943,001 shares during the period. Alliancebernstein L.P. grew its position in shares of Masimo by 1,276.9% in the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock valued at $156,604,000 after purchasing an additional 878,587 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Masimo by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 801,125 shares of the medical equipment provider’s stock worth $132,465,000 after purchasing an additional 8,239 shares during the period. 85.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MASI shares. Wells Fargo & Company increased their target price on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Thursday, April 10th. Piper Sandler boosted their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Raymond James increased their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has an average rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $152.07 on Wednesday. The firm has a market capitalization of $8.22 billion, a PE ratio of 104.88 and a beta of 1.28. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The business’s 50 day moving average is $166.89 and its 200-day moving average is $165.11.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Sell-side analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.